BoNT-A Does Not Affect Gross Energy Cost of Walking in Cerebral Palsy
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- For children with cerebral palsy (CP), a single injection of botulinum neurotoxin A (BoNT-A) into the calf muscles does not affect the gross energy cost of walking, according to a study published online July 26 in Developmental Medicine & Child Neurology.
Siri Merete Brændvik, from the Norwegian University of Science and Technology in Trondheim, and colleagues conducted a quadruple-blind, placebo-controlled, multicenter trial involving 61 children with spastic CP and classified in Gross Motor Function Classification System (GMFCS) levels I and II. Participants were randomly allocated to single injections of BoNT-A or 0.9 percent saline into the calf muscles.
The researchers found that the mean change in energy cost did not differ significantly between the groups at the primary time point of 12 weeks or at four weeks or 24 weeks after the injection. There was some evidence for a larger reduction in pain intensity for participants receiving BoNT-A with respect to secondary end points of walking capacity, habitual physical activity, perceived change in mobility tasks, and calf pain.
"The results suggest that BoNT-A injected into the calf muscles may reduce pain in children with CP classified in GMFCS levels I and II, although this requires further research," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-13 01:15
Read more
- Study Assesses Risk for 28-Day Hospitalization for Adults With RSV
- Clinicians Often Fail to Rescue Women With Complications After High-Risk Surgery
- 1 in 5 Americans' Drinking Water Tainted With PFAS Chemicals
- ACAAI: Many Anaphylaxis Protocols Are Incomplete, Outdated
- Higher Physical Activity Levels Can Increase Life Expectancy
- Overtreatment Common for Older Men With Prostate Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions